Geode Capital Management’s Anbio Biotechnology NNNN Stock Holding History

Geode Capital Management’s Portfolio NNNN Stock Details NNNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Buy	26,736 +973	+4%	+$24.4K	﹤0.01%	3711
2026 Q1	$662K	Hold	25,763	–	–	﹤0.01%	3484
2025 Q4	$775K	Hold	25,763	–	–	﹤0.01%	3452
2025 Q3	$960K	Buy	25,763 +8,633	+50%	+$388K	﹤0.01%	3393
2025 Q2	$542K	Buy	17,130 +70	+0.4%	+$670	﹤0.01%	3531
2025 Q1	$127K	Buy	+17,060	New	+$117K	﹤0.01%	3966

Other funds holding NNNN

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFS

Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return

LFG

Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return

Geode Capital Management's NNNN Position: Q2 2026 in Review

Geode Capital Management increased its Anbio Biotechnology (NNNN) stake by 3.8% in Q2 2026, buying an estimated $24.4K and bringing the position to 26,736 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #3711.

Geode Capital Management first reported a position in NNNN in Q1 2025 and has held it in 6 quarters since. The position peaked at $960K in Q3 2025. 12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

Geode Capital Management held 26,736 shares of Anbio Biotechnology worth $367K as of Q2 2026.
Geode Capital Management bought 973 Anbio Biotechnology shares in Q2 2026, an estimated $24.4K.
Anbio Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3711 holding.
Geode Capital Management first reported a position in Anbio Biotechnology in Q1 2025 and has held it in 6 quarters since.
Geode Capital Management's Anbio Biotechnology position peaked at $960K in Q3 2025.
12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.